Ra Anana

Researchers are evaluating the safety and effectiveness of NDV01 KIT, a fixed-dose combination of gemcitabine HCl and docetaxel, delivered directly into the bladder for patients with high-grade Non-Muscle Invasive Bladder Cancer (NMIBC). This Phase 2, open-label, single-arm study aims to assess how well this treatment works and its safety profile. The study also includes a pharmacokinetic sub-study to measure how the drugs are absorbed and processed in the body.

Researchers are studying phantom limb pain (PLP), a common and often severe condition experienced by most amputees for years after their amputation. This research focuses on preventing PLP from becoming chronic by using a new combined treatment of mirror therapy (MT) and transcranial direct current stimulation (tDCS) applied early during the acute stage of PLP. The study aims to understand whether this combined approach can reduce pain intensity, improve clinical symptoms related to amputation, and positively affect body perception and pain inhibition mechanisms. The study involves three groups of patients randomized into: no intervention, mirror therapy with sham tDCS, and mirror therapy with real tDCS. Participants will perform mirror therapy by watching the reflection of their intact limb while moving it for 20 minutes per session. The tDCS device delivers mild electrical stimulation to the brain's motor cortex for 20 minutes per session. Both treatments are self-administered at home, with a total of 20 sessions over 4 weeks. The sham tDCS mimics real stimulation sensations without delivering current, supporting a blinded study design. Participants will be closely monitored through assessments at five timepoints, including before treatment, during, and up to 8 weeks after completing the intervention. The main outcome measured is pain intensity using a visual scale comparing baseline pain to pain 4 weeks after treatment ends. Researchers will also evaluate behavioral markers and clinical features related to amputation. Safety, adherence, and effects on phantom sensations, negative emotions, body ownership, and pain inhibition will be tracked throughout the study conducted at three major rehabilitation centers in Israel.

Researchers are evaluating the use of Apixaban compared to Enoxaparin to prevent venous thromboembolism (VTE) in patients with spinal cord injuries during the acute and sub-acute phases. The study focuses on patients undergoing rehabilitation after spinal cord injury and aims to assess the effectiveness and safety of these anticoagulant treatments. Participants will receive either Enoxaparin at a dose of 40 mg once daily or Apixaban at 2.5 to 5 mg twice daily, with the exact Apixaban dose determined by the treating physician. Treatment duration varies by injury severity: 6 weeks for AIS grades C-D and 12 weeks for AIS grades A-B. Monitoring includes D-Dimer tests every two weeks and ultrasound Doppler scans at the start and end of treatment to evaluate for VTE. Throughout the study, bleeding events will be recorded, and hematocrit levels will be checked biweekly to monitor safety. The main outcome measured is the number of participants experiencing VTE over a two-year period. The study involves regular assessments to ensure participant safety and treatment adherence during the prescribed treatment period.

This research investigates whether giving patients Pregabalin early after spinal cord injury (SCI) can prevent the development of central pain. The study focuses on adults who arrive for rehabilitation within three months after SCI and have not yet developed central pain. It explores the effects of preventive drug therapy on pain regulation mechanisms in these patients. Participants are divided into two groups: two-thirds receive Pregabalin 75 mg twice daily for three months, while one-third receive no preventive treatment. This approach allows comparison of central pain development between those treated with Pregabalin and those who are not. Throughout the study, participants are monitored over one year to assess central pain development using measures like the McGill Pain Questionnaire at three months. Researchers evaluate pain outcomes to understand the preventive effects of Pregabalin, ensuring participant cooperation and informed consent during rehabilitation and follow-up.

Older adults undergoing inpatient rehabilitation often have low levels of physical activity, especially those with lower limb orthopedic conditions who face mobility challenges. This research aims to evaluate the feasibility and user experience of using a robotic system to support upper body physical training for people with these conditions during inpatient rehabilitation. The study focuses on how acceptable and suitable the training is, including attendance, engagement, adherence, enjoyment, and any unexpected adverse events. Participants will perform upper body exercises with guidance from a robotic trainer in a physical therapy hall. After consent and initial questionnaires, a physical therapist will select exercises tailored to each participant's abilities and goals. Training sessions occur three times per week for three weeks. During each session, the robot introduces itself, demonstrates exercises, and provides verbal instructions and feedback. Exercises include resistance training with weights and bands, plus flexibility stretches for the upper body and trunk. A physical therapist supervises all sessions to ensure safety and proper technique. Participants will log into the system using a unique number and self-practice the exercises under supervision. Data on exercise success will be collected automatically. After each session, participants rate their exertion using a scale on the robot's screen. Researchers will monitor attendance, engagement, and safety throughout the treatment period of 3 to 4 weeks. At the end of the training, participants complete questionnaires to share their experience, helping assess the feasibility of this robotic training approach.

Researchers are evaluating how a speaking valve affects breathing, swallowing, and vocal functions in adults with tracheostomy who have disturbances of consciousness and do not require mechanical ventilation. The study focuses on patients with brain injuries who are in an unresponsive wakefulness syndrome or minimally conscious state. The rationale is based on observations that the speaking valve may improve breathing and secretion management in these patients. Participants will use the Shiley132 phonate speaking valve device, which connects to the tracheostomy tube and is typically used to assist with vocalization. The study compares the effects of using this device during respiratory physical therapy sessions against a control group receiving no intervention. The device's influence on breathing and vocal function will be assessed during therapy. During the study, participants will be monitored for changes in oxygen saturation and breathing rate within 15 minutes of intervention. Evaluations include fiber optic examinations to check vocal cord movement and airway condition. The legal guardian must speak Hebrew to facilitate communication. Safety is monitored by excluding those with airway stenosis or inflammation and those with oxygen saturation below 90%.